ClinicalTrials.gg
RecruitingNCT07488923Updated Oct 16, 2026

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

A Phase 1 interventional study of ML261 in Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) and Gastroenteropancreatic NEC (GEP NEC), sponsored by Moonlight Bio, Inc. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Moonlight Bio, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 8, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 630 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
174th of 551
110 · median 55
Started
2026
with 37 others
Phase 1
183 of 630
24 open now
Primary completion
2028-03
later than 103 of 181 live
Registered
612th of 630
by date

Among the 630 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 174th largest by planned enrollment of the 551 interventional ones that give a count, is one of 38 that started in 2026, is one of 183 in phase 1, reaches primary completion later than 103 of the 181 other live ones, and was the 612th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 630 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

105 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs

03

Conditions studied

  • Small Cell Lung Cancer (SCLC )
  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
  • Gastroenteropancreatic NEC (GEP NEC)
  • Neuroendocrine Prostate Cancer (NEPC)

Keywords

  • Neuroendocrine carcinoma
  • DLL3
  • CAR T
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age at the time of signing the ICF
  • Have been previously treated with at least one line of systemic standard of care (SOC) anti-cancer therapy for their respective cancer indication. Participants with locally advanced disease who are eligible for curative resection will be excluded.
  • Have documented radiological disease progression/relapse during or after their most recent line of anti-cancer therapy with on imaging, as assessed by v1.1
  • Have and/or cytologically confirmed diagnosis of select advanced or R/R solid tumor in one of the following: R/R SCLC, R/R GEP-NEC, R/R high-grade NEPC, R/R epNEC with -documented DLL3 expression on archival tissue or fresh biopsy by local or central assessment. CNS NEC is excluded. Participants with mixed histologies for any of these indications qualify if the small cell/neuroendocrine tumor cell percentage is > 50%, except for high-grade NEPC where neuroendocrine component must be > 20%.
  • (ECOG) Performance Score (PS) 0 or 1
  • ≥12 weeks
  • Have adequate hematologic and end-organ function

Exclusion criteria

Exclusion Criteria:

  • Previous systemic anti-cancer therapies within the timeframes, as specified in the protocol.
  • Prior exposure/treatment with DLL3-targeted CAR T therapy or any other genetically engineered adoptive T cell therapy.
  • Prior allogeneic organ transplant (including bone marrow transplant).
  • Major surgical procedure within 4 weeks of the first dose of any study drug administration or anticipated to be in need of a major surgical procedure during the course of study.
  • Participants with toxicities (as a result of prior anti-cancer therapy) which have not recovered to baseline or v5.0 \<Grade 2, except for adverse events (AEs) not considered a likely safety risk: (e.g., alopecia, neuropathy, non- laboratory abnormalities).
  • Symptomatic ascites or effusions (pleural or pericardial) requiring intermittent drainage.
  • History of any other known to be active, with the exception of completely removed in situ cervical intra-epithelial neoplasia, non-melanoma skin cancer, ductal carcinoma in situ, early-stage prostate cancer that has been adequately treated, and other cancers from which the participant has been disease free for 3 years or longer or does not require treatment and in the opinion of investigator after discussion with the medical monitor are not likely to impact the patient's .
  • One or more of the following cardiac criteria: Unstable angina, Myocardial infarction within 6 months prior to Screening, Class III to IV heart failure, clinically important abnormalities in rhythm, conduction, or morphology of resting (e.g., complete left bundle branch block or third-degree heart block)
  • Acute venous thromboembolism (VTE). VTEs without hemodynamic compromise, treated with stable doses of anticoagulants are allowed.
  • Presence of clinically significant CNS pathology:

    • seizure disorder, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, or cerebellar disease. History of these disorders requires discussion with the medical monitor.
    • Presence of clinically active psychosis.
    • Known unless asymptomatic and not requiring for at least 2 weeks prior to the first dose of any study drug administration.
  • Active systemic disease or any other condition that requires, or is anticipated to require, systemic treatment with steroids or other systemic agents, or participants who have received such agents within 4 weeks of leukapheresis and ML261 administration (further details provided in protocol body).
  • Evidence of interstitial lung disease (such as idiopathic pulmonary fibrosis) or active pneumonitis of any etiology requiring treatment.
  • Any active infection (defined as symptoms, signs, or radiographic) of bacterial, viral, or fungal or unknown etiology requiring systemic therapy within 14 days of leukapheresis. Participants with clinical and/or laboratory evidence of persistent infection will be excluded.
  • Uncontrolled medical, psychological/psychiatric, or social condition that would interfere with the participant's participation or compromise the objectives of the study in the opinion of the Investigator and/or the Sponsor.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    ML261

    DLL3-Directed Chimeric Antigen Receptor T cells (CAR T)

    Biological: ML261

Interventions

  • BiologicalML261

    DLL3 directed autologous Chimeric Antigen Receptor T cells

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs) listed during the DLT observation period

    Graded according to Common Terminology Criteria for Adverse Events (CTCAE) or American Society for Transplantation and Cell Therapy (ASTCT) criteria

    Time frame: 28 days

Secondary outcomes

  1. Incidence of treatment-emergent AEs (TEAEs), Grade ≥3 TEAEs, serious AEs (SAEs), and AEs of special interest (AESIs). Clinically significant laboratory abnormalities / changes from baseline in safety laboratory test results

    Graded according to Common Terminology Criteria for Adverse Events (CTCAE v5.0) or American Society for Transplantation and Cell Therapy (ASTCT) criteria (for grading CRS and ICANS)

    Time frame: Through study completion; up to 2 years

  2. Characterize the molecular pharmacokinetic (PK) profile of ML261 after dosing

    Measurement of ML261 associated vector copy number (VCN) in peripheral blood over time

    Time frame: Through study completion; up to 2 years

  3. Evaluate the preliminary efficacy of ML261 after dosing

    Measured by Response Evaluation Criteria In Solid Tumors (RECIST v1.1)

    Time frame: Through study completion; up to 2 years

Other outcomes

  1. Evaluate the immunogenicity of ML261 after dosing

    Number of participants with presence of anti-ML261 antibodies over time

    Time frame: Through study completion; up to 2 years

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 21 months after the start.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 21 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 23, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Aug 2030
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Fred Hutch Cancer Center · Seattle, United States
Oct 8, 2026
Site contacts
Changed at 7 sites. See the sites
Show 7 sites
  • Washington University Medicine · St Louis, United StatesContact added a•••@wustl.edu · •••5116
  • Hackensack University Medical Center · Hackensack, United StatesContact added O•••@hmhn.org · •••1777
  • NYU Langone Health · New York, United StatesContact added D•••@nyulangone.org
  • UT Southwestern Medical Center · Dallas, United StatesContact added S•••@utsouthwestern.edu · •••9597
  • MD Anderson Cancer Center · Houston, United StatesContact added e•••@mdanderson.org · •••3934
  • Sarah Cannon Research Institute (SCRI) · Nashville, United StatesContact added •••4812
  • Fred Hutch Cancer Center · Seattle, United StatesContact added h•••@fredhutch.org · •••1024
across 2 updates, Oct 8, 2026 – Oct 16, 2026
Show all 2 updates
  1. Oct 16, 2026
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Sarah Cannon Research Institute (SCRI) · Nashville, United StatesContact added •••4812
    • Fred Hutch Cancer Center · Seattle, United StatesContact added h•••@fredhutch.org · •••1024
  2. Oct 8, 2026
    1 site added
    Show site
    • Fred Hutch Cancer Center · Seattle, United States
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Washington University Medicine · St Louis, United StatesContact added a•••@wustl.edu · •••5116
    • Hackensack University Medical Center · Hackensack, United StatesContact added O•••@hmhn.org · •••1777
    • NYU Langone Health · New York, United StatesContact added D•••@nyulangone.org
    • UT Southwestern Medical Center · Dallas, United StatesContact added S•••@utsouthwestern.edu · •••9597
    • MD Anderson Cancer Center · Houston, United StatesContact added e•••@mdanderson.org · •••3934

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07488923
Lead sponsor
Moonlight Bio, Inc
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Jun 23, 2026
Primary completion
Mar 2028 (estimated)
Completion
Aug 2030 (estimated)
Last update
Oct 16, 2026

Study contacts

Moonlight Bio Clinical Team
Contact
MLTrials@moonlightbio.us
206-647-6168

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion